Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Antibodies are the fastest growing segment of the pharmaceutical market, and with modern engineering technologies antibodies can be programmed to target devastating diseases. Within the immune system, antibodies fight invading bacteria and viruses. High-quality synthetic antibodies directed to disease-related targets have immense therapeutic potential. Development of cell-based assays to enable rapid identification of functionally active antibodies is a critical step in the commercialization process. The proposed research project will involve screening of binders against disease-associated targets; antibodies showing clinical relevancy will be considered for entry into the clinical trial pipeline. The newly formed Centre for the Commercialization of Antibodies and Biologics (CCAB) will bridge the research and discovery occurring at the Donnelly Centre with industry partners to enable accelerated delivery of new therapies to fight diseases such as cancer, arthritis, and Crohn’s disease. CCAB will facilitate commercialization of antibodies by leveraging a world-class technology platform and experienced product development professionals.
Jason Moffat
Carly Griffin
Centre for the Commercialization of Antibodies and Biologics
Biochemistry / Molecular biology
Pharmaceuticals
University of Toronto
Elevate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.